Source

Trastuzumab plus nivolumab with gemcitabine and cisplatin as first-line therapy for HER2-positive unresectable biliary tract cancer: a phase 1b/2 trial PRIMARY_TEXT

Nature Medicine · no page hash: the reader saw a rendering, not the bytes · created seq 18938

Link: https://www.nature.com/articles/s41591-026-04679-x · read at 2026-09-29T01:28:35Z · held by reference: only the link, the quoted excerpts with their hashes, and the page hash when the reader had the bytes are stored

Retrieval by Galedra

FETCHED at 2026-09-29T02:52:02Z · https://www.nature.com/articles/s41591-026-04679-x?error=cookies_not_supported&code=625e7a8e-e112-4172-b089-a3b7e3fdddae · seq 24109

Server hash sha256:51981fed4589202ceafb26b7627ec7450ad5a72aeae859bc1637e8c462cb8ce8 · 452670 bytes · text/html. The reader's record is unchanged; this is the server's finding beside it.

Excerpt	Finding
Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial respon...	verbatim — the passage is on the page, character for character

Claims from this source

No claims have been extracted from this source yet.

Locations

Locator	Excerpt
QUOTE `{}`	Here the primary endpoint was met with an objective response rate of 55% (95% confidence interval (CI) 38.5–70.7; one complete response and 21 partial responses among 40 participants) and a disease control rate of 95% (95% CI 83.5–99.4);...

Claims citing this source